title: Successful treatment of diffuse large B-cell lymphoma in a patient with ataxia telangiectasia using rituximab.
abstract: Ataxia-telangiectasia (A-T) is an autosomal recessive disorder characterized by cerebellar ataxia, telangiectasia, immune defect, and predisposition to leukemia/lymphoma. Because of their hypersensitivity to DNA-damaging agents, patients with A-T may require special consideration. However, an optimal strategy for these patients has not been established. Here, we describe an A-T female with diffuse large B-cell lymphoma successfully treated with rituximab combined with reduced-dose chemotherapy. Given the high incidence of hematopoietic malignancies in patients with A-T, and the hypersensitivity of these patients to DNA-damaging agents, we discuss whether a reduced-dose chemotherapy with a molecular targeting agent may be of merit.
authors: Department of Pediatrics and Developmental Biology, Graduate School of Medicine, Tokyo, Japan.
authors: Shizuka
authors: S
authors: Machida
authors: Daisuke
authors: D
authors: Tomizawa
authors: Hiroyuki
authors: H
authors: Tamaichi
authors: Teppei
authors: T
authors: Okawa
authors: Akifumi
authors: A
authors: Endo
authors: Kohsuke
authors: K
authors: Imai
authors: Masayuki
authors: M
authors: Nagasawa
authors: Tomohiro
authors: T
authors: Morio
authors: Shuki
authors: S
authors: Mizutani
authors: Masatoshi
authors: M
authors: Takagi
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D001260:Ataxia Telangiectasia / Q000150:complications*; D005260:Female; D006801:Humans; D007223:Infant; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab